- المشتركون
- التغطية البريدية
- ER - نسبة المشاركة
جاري تحميل البيانات...
جاري تحميل البيانات...
Combination unlocks new future value-creation opportunities and is expected to be immediately accretive to BD revenue growth, adjusted gross margin, adjusted operating margin and adjusted EPS...
CinRx Pharma’s most prominent spinout is CinCor Pharma, which was acquired by AstraZeneca last year. The startup creator will apply its new capital toward current programs and to expand to additional areas of unmet medical need.
Bolstered by a full FDA approval for its primary immunoglobulin A nephropathy (IgAN) treatment Tarpeyo, Calliditas has earned the attention of Japanese chemical giant Asahi Kasei. | Asahi Kasei has made a cash offer to acquire Calliditas in a deal worth 11.16 billion Swedish crowns ($1.06 billion), the companies announced Tuesday. Asahi’s bid represents a 74% premium to Calliditas' prior closing price.